 DALLAS, May 17, 2021 PRNewswire -- Corporate Updates YTD SWK has closed two financings totaling up to 14.0 million Enteris BioPharma subsidiary announced completion of manufacturing facility expansion and launch of CDMO business SWK to form a strategic review committee to identify, review and explore strategic alternatives to maximize stockholder value Marcus Pennington named to Board of Directors First Quarter 2021 Finance Receivables Segment Updates: As of March 31, 2021, tangible book value per share was 16.31, a 10.6 increase from March 31, 2020 For the first quarter 2021, finance portfolio effective yield was 13.8, a 40-bps increase compared with 13.4 for the first quarter 2020 For the first quarter 2021, finance portfolio realized yield was 16.7, compared to 16.2 for the first quarter 2020 Core finance receivables business generated adjusted non-GAAP net income of 6.8 million for the quarter ended March 31, 2021, a 39 increase compared to 4.9 million for the quarter ended March 31, 2020 As of March 31, 2021, total investment assets were 219.0 million, a 21.1 increase from March 31, 2020 Post quarter close, two borrowers experienced liquidity events and repaid SWK, which realized a cumulative 1.5x MOIC multiple on invested capital on capital deployed, excluding warrants in publicly traded Harrow Health, which SWK continues to own SWK Holdings Corporation Nasdaq: SWKH, a life sciences focused specialty finance company catering to small and mid-sized companies, today provided a business update and announced its financial and operating results for the first quarter ended March 31, 2021. During the first quarter of 2021, SWK generated further value creation highlighted by the 16.7 realized yield in our finance receivables segment and continued strong credit trends, stated Winston Black, Chairman and CEO of SWK. 